jcm-logo

Journal Browser

Journal Browser

Contemporary Coronary Intervention: Innovation, Evidence, and Patient-Centred Outcomes

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 20 August 2026 | Viewed by 583

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Cardiology, Prince of Wales and Bankstown-Lidcombe Hospitals, Sydney, NSW, Australia
2. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
3. Faculty of Medicine, Western Sydney University, Sydney, NSW, Australia
Interests: complex coronary intervention; coronary imaging; coronary physiology; drug coated balloons; cardio-oncology; environmental cardiology; meta-analyses; systematic review; randomised controlled trials; precision medicine

Special Issue Information

Dear Colleagues,

The Journal of Clinical Medicine invites submissions for a Special Issue, “Contemporary Coronary Intervention: Innovation, Evidence, and Patient-Centred Outcomes”, which focuses on contemporary advances in coronary intervention. This collection will highlight emerging technologies and patient-centred approaches that shape modern revascularisation. We welcome original research and comprehensive reviews addressing physiological and imaging-guided strategies, optimisation of complex lesions, and long-term clinical outcomes. Submissions exploring innovation, implementation, and the integration of precision techniques in routine practice are particularly encouraged. This issue aims to provide clinicians and researchers with a comprehensive, authoritative resource on the evolving landscape of coronary intervention.

Dr. Kevin Liou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • percutaneous coronary interventions
  • coronary imaging
  • coronary physiology
  • precision medicine
  • CHIP PCI
  • stent-less technologies
  • clinical outcomes
  • pharmacotherapy in PCI
  • biomarkers
  • artificial intelligence in PCI
  • sustainability in PCI

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

16 pages, 1470 KB  
Systematic Review
Drug-Coated Balloons in Side Branch Treatment in True Coronary Bifurcation Lesions: A Meta-Analysis and Systematic Review
by Olivia Stainer, Milica Milosavljevic and Kevin Liou
J. Clin. Med. 2026, 15(7), 2489; https://doi.org/10.3390/jcm15072489 - 24 Mar 2026
Viewed by 386
Abstract
Background/Objectives: Coronary bifurcation lesions (CBLs) are common, and the treatments remain nuanced. Side branch (SB) patency is a key determinant of clinical success in CBL intervention. In this paper, data exploring the routine use of drug-coated balloons (DCBs) in the SB is [...] Read more.
Background/Objectives: Coronary bifurcation lesions (CBLs) are common, and the treatments remain nuanced. Side branch (SB) patency is a key determinant of clinical success in CBL intervention. In this paper, data exploring the routine use of drug-coated balloons (DCBs) in the SB is presented as an alternative to standard plain old balloon angioplasty (POBA). Methods: A meta-analysis was performed comparing DCBs in the SB to POBA after drug-eluting stent (DES) implantation in the main vessel (MV) of a true CBL. Outcomes including myocardial infarction (MI), target lesion revascularisation (TLR), cardiac death, and late lumen loss (LLL) up to 1 year post-procedure are reported. Results: Six studies comprising of 1982 patients were included in the analyses. Patients were predominantly male, and the mean age was >60 years. Four studies included patients with acute coronary syndrome. The primary outcomes were a statistically significant reduction in MI rate (OR 0.38, 95% CI 0.19–0.76, p = 0.006), and in the TLR rate (OR 0.45, 95% CI 0.23–0.87, p = 0.02) in the DCB group compared to the control. There was no significant difference in cardiac death. Furthermore, there was a significant reduction in SB LLL in the DCB group (Mean difference −0.22mm, 95% CI −0.33–−0.11mm, p = 0.0001). Conclusions: Following DES implantation in the MV of a true CBL, this analysis demonstrated that DCBs in the SB is superior to POBA in reducing MI, TLR, and LLL of the SB. Large, randomized trials are required to consolidate the role of DCB in the treatment of CBL. Full article
Show Figures

Figure 1

Back to TopTop